Nuveen
ODTX icon

Nuveen’s Odyssey Therapeutics ODTX Stock Holding History

Nuveen’s Portfolio ODTX Stock Details ODTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$510K Buy
+22,973
New +$488K ﹤0.01% 3369

Other funds holding ODTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Pavaki Capital Management
Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return

Nuveen's ODTX Position: Q3 2026 in Review

Nuveen opened a new position in Odyssey Therapeutics (ODTX) in Q3 2026: 22,973 shares worth $510K. The stake represents ﹤0.01% of the portfolio and ranks #3369 among its holdings.

18 funds tracked by Wall St. Rank hold ODTX as of Q3 2026.

  • Nuveen held 22,973 shares of Odyssey Therapeutics worth $510K as of Q3 2026.
  • Odyssey Therapeutics was a new Nuveen position in Q3 2026.
  • Odyssey Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q3 2026, its #3369 holding.
  • 18 funds tracked by Wall St. Rank held Odyssey Therapeutics as of Q3 2026.

Based on Nuveen's 13F filing for Q3 2026, filed 10 Nov 2026.